洋地黄糖苷在心衰治疗中的疗效与安全性:一项Meta分析
该Meta分析纳入3项安慰剂对照随机临床试验、共9013例射血分数轻度降低或降低的心衰患者,评估洋地黄糖苷对临床结局的影响。结果显示洋地黄糖苷组主要复合终点(心血管死亡或首次心衰恶化事件)风险低于安慰剂组(HR 0.85,95%CI 0.80-0.90),主要驱动因素为心衰恶化事件减少(HR 0.75,95%CI 0.69-0.81),而心血管死亡和全因死亡无显著差异。
要点
- 洋地黄糖苷可降低HFmrEF或HFrEF患者心血管死亡或首次心衰恶化复合终点风险。
- 获益主要来自心衰恶化事件减少,心血管死亡和全因死亡未见显著下降。
- 亚组间无异质性,提示获益不受基础心衰治疗程度或洋地黄类型影响。
核心结论
- 洋地黄糖苷治疗与HFmrEF或HFrEF患者心血管死亡或首次心衰恶化复合终点风险降低相关,主要源于心衰恶化事件减少。
- 洋地黄糖苷未显著降低心血管死亡或全因死亡风险。
研究设计与样本
- 系统检索PubMed自建库至2026年3月1日,纳入安慰剂对照随机临床试验,要求样本量>1000例且英文发表。
- 共纳入3项研究、9013例HFmrEF或HFrEF患者,加权平均年龄64.5岁(加权SD 11.2),女性22%、男性78%。
- 采用固定效应模型估计风险比(HR)及95%CI,偏倚风险用Cochrane RoB 2工具评估。
主要发现
- 主要复合终点在洋地黄糖苷组发生1852/4510例(41%),安慰剂组2037/4503例(45%),HR 0.85(95%CI 0.80-0.90),P<.001。
- 首次心衰恶化事件在洋地黄糖苷组1183例(26%),安慰剂组1474例(33%),HR 0.75(95%CI 0.69-0.81),P<.001。
- 心血管死亡在两组均为1224例(各27%),HR 0.99(95%CI 0.92-1.07),P=.81。
- 全因死亡在洋地黄糖苷组1466例(32%),安慰剂组1497例(33%),HR 0.97(95%CI 0.90-1.04),P=.41。
- 按试验、洋地黄糖苷类型或基础心衰治疗程度均无统计学显著异质性。
临床怎么用
- 对HFmrEF或HFrEF患者,可考虑在基础治疗上加用洋地黄糖苷以减少心衰恶化事件。
- 应用时需注意洋地黄糖苷未显示降低死亡风险,主要获益为减少心衰恶化住院或急诊事件。
局限性
- 仅纳入3项随机临床试验,证据体量有限。
- 纳入标准限制为样本量>1000例和英文发表,可能遗漏其他相关研究。
- 原文未报告纳入研究的随访时长及具体不良事件数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Digitalis glycosides may be used as additional therapy in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or HF with reduced EF (HFrEF). OBJECTIVE: To assess the effect of digitalis glycosides on clinical outcomes in patients with HFmrEF or HFrEF. DATA SOURCES AND STUDY SELECTION: PubMed was searched from inception to March 1, 2026, using medical subject headings and keywords related to digitalis glycosides and HF. The review was restricted to placebo-controlled randomized clinical trials including more than 1000 patients and articles published in the English language. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 reviewers who followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Risk of bias was assessed with the Cochrane Risk of Bias tool (version 2). A fixed-effects model was used to estimate the hazard ratios (HRs) with 95% CIs. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of time to cardiovascular death or first worsening HF event. Secondary outcomes included individual components of the composite outcome and time to all-cause death. RESULTS: A total of 3 studies met the inclusion criteria and included 9013 patients with HFmrEF or HFrEF (weighted mean age, 64.5 [weighted SD, 11.2] years; 22% female and 78% male). The composite outcome of cardiovascular death or first worsening HF event occurred in 1852 of 4510 patients (41%) in the digitalis glycoside group vs 2037 of 4503 patients (45%) in the placebo group (HR, 0.85 [95% CI, 0.80-0.90]; P < .001). First worsening HF event occurred in 1183 (26%) patients in the digitalis glycoside group vs 1474 (33%) patients in the placebo group (HR, 0.75 [95% CI, 0.69-0.81]; P < .001). There were 1224 cardiovascular events in the digitalis glycoside group vs 1224 in the placebo group (27% of participants in each group; HR, 0.99 [95% CI, 0.92-1.07]; P = .81) and there were 1466 vs 1497, respectively, all-cause deaths (32% of participants vs 33%; HR, 0.97 [95% CI, 0.90-1.04]; P = .41). There was no statistically significant heterogeneity by trial, type of digitalis glycoside treatment, or extent of background HF therapy. CONCLUSIONS AND RELEVANCE: Treatment with digitalis glycosides was associated with a lower risk of the composite of cardiovascular death or first worsening HF event in patients with HFmrEF or HFrEF, mainly through a lower risk of worsening HF events. There was no statistically significant interaction with important study characteristics, including the extent of HF background therapy or type of digitalis glycosides treatment. These results suggest digitalis glycosides may be used as additional medical therapy to reduce worsening HF events in patients with HFmrEF or HFrEF.
引用
- Damman K, van Veldhuisen DJ, Bauersachs J, et al. Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis. JAMA. 2026. PMID: 42106991. doi:10.1001/jama.2026.7886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。